As the COVID-19 pandemic worsens, the clinical cancer community is grappling with how to continue providing access to experimental but potentially lifesaving therapies while keeping immunocompromised patients safe. To that end, cancer centers are making changes to their clinical trial programs, while pharmaceutical companies are deciding how-or whether-trials should continue.

中文翻译：

---

随着COVID-19激增，临床研究进展缓慢。

随着COVID-19大流行病的恶化，临床癌症界正在努力如何继续提供实验性但有可能挽救生命的疗法，同时又要保护免疫受损患者的安全。为此，癌症中心正在改变其临床试验计划，而制药公司正在决定应如何进行或是否应继续进行试验。